MedTrace Logo

Study on the Effect of Mitomycin C 0.02% on the Corneal Endothelial After Photorefractive Keratectomy in Moderate Myopia

NCT00999973 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-10-22

No results posted yet for this study

Summary

In this study 126 eyes in 63 patients with moderate bilateral myopia and astigmatism between -3 and -5 (SE difference between two eyes should not be more than 0.75 and the residual corneal thickness\>350 μ ) were entered in the study. One eye went randomly under PRK with mitomycin C 0.02% in 15 min and then the other eye went under the operation without MMC. UCVA,BCVA, refractory error after the operation and the number of endothelial cells before and after the surgery would be compared in 6 months.

Conditions

  • Myopia

Interventions

DRUG

Mitomycin C 0.02%

DRUG

Placebo

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00999973 on ClinicalTrials.gov